Inonza 1mg injection is an anticancer medication with an active ingredient called Inotuzumab ozogamicin. It is used to treat adults with acute lymphoblastic Leukemia. It is intended when patients have failed to respond to other treatments. Acute lymphoblastic Leukemia (ALL) refers to the accumulation of white blood cells that have not matured due to the abnormal production of white blood cells in the bone marrow.  

Do not take Inonza 1mg injection if you are allergic to Inotuzumab ozogamicin or any other ingredients of this medicine, if you have or have any history with any liver disease, such as venoocculusive disease (damaged liver blood vessels), cirrhosis, nodular regenerative hyperplasia (signs and symptoms of portal hypertension due to chronic use of medicine), or active hepatitis (inflammation of the liver) and blood clot. This medicine is not recommended for children and adolescents.  

Before starting the Inonza 1mg treatment, inform your doctor if you have signs and symptoms of tumour lysis syndrome, a low number of blood cells (neutrophils), elevations in amylase or lipase enzymes, or a history of QT interval prolongation. Notify your doctor if you are pregnant or planning to get pregnant during and after the treatment for up to 8 months. Use effective contraception during and after eight months of treatment for women and five months for men. Discuss with your doctor for more fertility concerns. Certain tests will be taken to monitor the blood cell count, liver enzyme, and QT interval.

• Acute lymphoblastic Leukemia

Inotuzumab ozogamicin in Inonza 1mg injection targets a protein called CD22, which is commonly expressed by blood cancer (ALL) cells. After attaching to this protein, this medicine disturbs the DNA of the cancer cells and eventually kills them.

Inform your healthcare provider about all the medicines you take, including prescription, over-the-counter, nutritional, supplements, and herbal products. In particular, tell your doctor if you are taking medicines for blood pressure or other heart conditions. Certain medications may interact with Inonza 1mg and reduce its effectiveness by causing undesirable side effects. 

• Store Inonza 1mg Injection in the refrigerator (2°C to 8°C)
• Do not freeze
• keep the injection away from the reach of children and pets.
• If you have missed any dosing appointments, inform your doctor and schedule immediately.

A trained doctor or nurse should only administer it. Do not self-administer the Inonza 1mg injection. Your doctor will decide the dose and duration of your treatment based on the disease severity and other factors. It will be given as an intravenous infusion, and you will be monitored carefully for unwanted side effects. 

Side effects are unwanted symptoms caused by medicines. Even though all medications cause side effects, not everyone gets them.

Serious

• Breathing trouble
• Chills
• Rapid weight gain
• Abnormal liver function values
• Frequent bleeding and bruising
• Infusion-related reaction (fever, chill, breathing trouble)
• Venoocclusive liver disease (rapid weight gain, right upper abdomen pain, swelling of the liver)
• The lower number of blood cells
• Tumor lysis syndrome
• Changes in the electrical activity of the heart

Common

• Anaemia
• Tiredness
• Infection
• Bleeding
• Fever
• Nausea
• Headache
• Abnormal blood values
• Stomach pain
• High bilirubin value
• Low appetite
• Mouth inflammation
• Constipation
• Diarrhea
• Swelling of abdomen

Dose adjustments will be made based on the response to the treatment. Pre-medicine will be given to reduce the infusion reactions, keep hydrated, and prevent tumour lysis syndrome and other side effects. There is limited information on the safety of Inonza 1mg Injection in renal failure patients; inform your physician if you have kidney disease. Notify your doctor if you experience any side effect symptoms, as your doctor may change the dosage of this medicine or give additional medicine to reduce the effect of the side effects. Men should use effective contraception during and after the last dose of the treatment. 

1. Pfizer Limited, Electronic Medicines Compendium (EMC), [Revised on Jan 2021] [Accessed on 04 May 2023], https://www.medicines.org.uk/emc/files/pil.650.pdf
2. Wyeth Pharmaceuticals Inc., US Food & Drug Administration, [Revised on Aug 2017] [Accessed on 04 May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf
3. H.G. Watson, J.I.O. Craig, L.M. Manson, Blood disease, Davidson's Principles and Practice of Medicine, 22nd Edition, 2014, 989-1056.
4. D. Bhojwani et al., Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic Leukemia, Leukemia (2019) 33:884–892, https://www.nature.com/articles/s41375-018-0265-z.pdf